2/3 COMpAAAS Tripartite: ART-CC, KP, and VA
2/3 COMpAAAS 三方:ART-CC、KP 和 VA
基本信息
- 批准号:9408427
- 负责人:
- 金额:$ 60.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-15 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAffectAgeAgingAlcohol abuseAlcohol consumptionAlcohol or Other Drugs useAlcoholsAmericanAnti-Retroviral AgentsAwardBiological MarkersBirthCaliforniaCaringClinicalCocaineCohort StudiesCollaborationsComorbidityCountryDataData SetDrug InteractionsDrug usageElectronic Health RecordEuropeEuropeanGenderGoalsGrantHIVHIV InfectionsHIV-1HIV/HCVHealthHealthcare SystemsHepatitis CHospitalizationIndividualInfectionInterventionLeadMalignant NeoplasmsMarijuanaMeasurementMeasuresMediatingMedicalMental DepressionMethamphetamineMethodsNational Institute on Alcohol Abuse and AlcoholismNorth AmericaOpioidOutcomePatient Self-ReportPatientsPharmaceutical PreparationsPhysiologicalPolypharmacyPreventive carePreventive healthcareProtocols documentationRNARaceReportingResearchRiskSample SizeSamplingSiteSmokingStandardizationSystemTobaccoTobacco useUnited States National Institutes of HealthUpdateVeteransWomanalcohol consequencesalcohol exposurealcohol interventionalcohol measurementalcohol riskalcohol use disorderantiretroviral therapybasecohortdata exchangedata formatdata sharingdrinkingfrailtyimproved outcomeindexinginnovationmembermenmen who have sex with menmortalityphosphatidylethanolprospectivesmoking interventiontherapy designtherapy developmenttobacco exposure
项目摘要
PROJECT SUMMARY/ABSTRACT
HIV+ adults who drink are already physiologically frail due to HIV infection, comorbidity (including hepatitis C
infection), polypharmacy and associated substance use. In this setting, biomedical consequences of alcohol
use can occur with moderate use and are often unappreciated or misattributed. The “Consortium to improve
OutcoMes in HIV/Aids, Alcohol, Aging & multi-Substance” (COMpAAAS) is supported by NIH/NIAAA award
U24AA020794 to study this issue in a single sample, the Veterans Aging Cohort Study (VACS) (~50,000 HIV+
US veterans demographically matched to ~100,000 uninfected comparators). VACS will employ a direct
alcohol biomarker (Phosphatidyl-ethanol [PEth] and a validated measure of physiologic frailty (VACS Index). In
this set of three applications, the Antiretroviral Therapy Cohort Collaboration (ART-CC) and Kaiser
Permanente (KP) teams join the Veterans Healthcare System (VA) team as COMpAAAS Tripartite: ART-CC,
KP, and VA. Our long term goal is to inform alcohol intervention design and implementation. Together we
propose to study biomedical consequences of alcohol and associated substance use in HIV, extending the
scope and generalizability of VACS to multiple healthcare systems in North America and Europe and
substantially increasing sample size and diversity of HIV+ subjects. Importantly, COMpAAAS Tripartite also
expands the sample of uninfected comparators, a critically important group if we are to understand how alcohol
differentially affects biomedical outcomes in HIV. KP will be able to identify demographically-matched
uninfected comparators from their Northern California region. A new VA sample of veterans born in 1945-1965
(Birth Cohort) expands access to Hepatitis C infected (HCV+) and women comparators. The tripartite group
will also participate in an HIV+ substudy (n=2250), The Medications, Alcohol, Substance Use in HIV Study
(MASH), in which new data on potentially inappropriate medications (PIMS) and biomarkers for alcohol and
substances (tobacco, marijuana, opioids, cocaine, and methamphetamine) will be collected. As the lead site
for Aim 2, KP will examine the impact of alcohol and smoking on HIV outcomes, preventive care, and medical
comorbidities. We anticipate that among HIV+ individuals, hazardous alcohol use, alcohol use disorders and
smoking will negatively impact each of these outcomes; and that these effects will be amplified in HIV+
individuals compared with uninfected individuals. Initially, analyses will use electronic health record data
including self-reported alcohol and substance use. Analyses will be repeated in the final year correcting for
biases in self-reported alcohol and substance use based upon MASH results. Consistent with the RFA, all
grants contribute data for all aims, have identical aims and protocols. This application addresses key
interactions between alcohol and tobacco use, antiretrovirals, and medications that may increase mortality,
hospitalization, frailty, and adversely impact preventive health care. We anticipate findings may lead to
innovative intervention development, such as combined alcohol, smoking and preventive care interventions.
项目概要/摘要
饮酒的 HIV 阳性成年人由于 HIV 感染、合并症(包括丙型肝炎)而生理上已经很脆弱。
感染)、复方用药和相关物质使用。在这种情况下,酒精的生物医学后果
使用可以在适度使用的情况下发生,并且常常不被重视或被错误归因。 “改善联盟”
“艾滋病毒/艾滋病、酒精、衰老和多种物质的结果”(COMpAAAS) 得到 NIH/NIAAA 奖的支持
U24AA020794 在单个样本中研究这个问题,即退伍军人老龄化队列研究 (VACS)(约 50,000 HIV+
美国退伍军人在人口统计上与约 100,000 名未感染的对照者相匹配)。 VACS 将直接聘用
酒精生物标志物(磷脂酰乙醇 [PEth] 和经过验证的生理虚弱指标(VACS 指数)。
这组三个应用程序,抗逆转录病毒治疗队列协作 (ART-CC) 和 Kaiser
Permanente (KP) 团队作为 COMpAAAS 三方加入退伍军人医疗保健系统 (VA) 团队:ART-CC、
KP 和 VA。我们的长期目标是为酒精干预措施的设计和实施提供信息。我们一起
提议研究酒精和相关物质使用对艾滋病毒的生物医学影响,扩大
VACS 对北美和欧洲多个医疗保健系统的范围和普遍性
大幅增加 HIV+ 受试者的样本量和多样性。重要的是,COMpAAAS 三方还
扩大了未感染的比较者的样本,如果我们要了解酒精如何影响,这是一个至关重要的群体
对艾滋病毒的生物医学结果有不同的影响。 KP 将能够识别人口统计匹配的
来自北加州地区未感染的对照者。 1945-1965 年出生的退伍军人的新 VA 样本
(出生队列)扩大了丙型肝炎感染者 (HCV+) 和女性对照者的接触范围。三方组
还将参加 HIV+ 子研究 (n=2250),HIV 研究中的药物、酒精和药物使用
(MASH),其中关于潜在不适当药物(PIMS)和酒精和酒精生物标志物的新数据
将收集物质(烟草、大麻、阿片类药物、可卡因和甲基苯丙胺)。作为主导站点
对于目标 2,KP 将研究酒精和吸烟对艾滋病毒结果、预防保健和医疗的影响
合并症。我们预计,在艾滋病病毒感染者中,危险性饮酒、酒精使用障碍和
吸烟会对这些结果产生负面影响;这些影响在 HIV+ 中会被放大
个体与未感染个体的比较。最初,分析将使用电子健康记录数据
包括自我报告的酒精和药物使用情况。分析将在最后一年重复进行,以纠正
根据 MASH 结果,自我报告的酒精和药物使用存在偏差。与 RFA 一致,所有
赠款为所有目标提供数据,具有相同的目标和协议。该应用程序解决了关键
饮酒和吸烟、抗逆转录病毒药物和可能增加死亡率的药物之间的相互作用,
住院、虚弱并对预防性医疗保健产生不利影响。我们预计调查结果可能会导致
创新干预措施的发展,例如结合酒精、吸烟和预防保健干预措施。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Derek D Satre其他文献
The impact of motivational interviewing to reduce alcohol use among adults in treatment for depression
- DOI:
10.1186/1940-0640-8-s1-a65 - 发表时间:
2013-09-01 - 期刊:
- 影响因子:3.200
- 作者:
Derek D Satre;Stacy A Sterling;Amy Leibowitz;Wendy Lu;Constance Weisner - 通讯作者:
Constance Weisner
Derek D Satre的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Derek D Satre', 18)}}的其他基金
Assessing Syndemics of Cardiovascular Disease in People with and without HIV
评估感染者和未感染者的心血管疾病综合征
- 批准号:
10683388 - 财政年份:2022
- 资助金额:
$ 60.76万 - 项目类别:
Assessing Syndemics of Cardiovascular Disease in People with and without HIV
评估感染者和未感染者的心血管疾病综合征
- 批准号:
10541067 - 财政年份:2022
- 资助金额:
$ 60.76万 - 项目类别:
Mentoring alcohol use intervention research in health care settings
指导医疗机构中的酒精使用干预研究
- 批准号:
10475266 - 财政年份:2018
- 资助金额:
$ 60.76万 - 项目类别:
Mentoring alcohol use intervention research in health care settings
指导医疗机构中的酒精使用干预研究
- 批准号:
10241959 - 财政年份:2018
- 资助金额:
$ 60.76万 - 项目类别:
Mentoring alcohol use intervention research in health care settings (administrative supplement)
指导医疗机构中的酒精使用干预研究(行政补充)
- 批准号:
10669523 - 财政年份:2018
- 资助金额:
$ 60.76万 - 项目类别:
Mentoring alcohol use intervention research in HIV health care settings
指导艾滋病毒卫生保健机构中的酒精使用干预研究
- 批准号:
10762918 - 财政年份:2018
- 资助金额:
$ 60.76万 - 项目类别:
2/3 COMpAAAS Tripartite: ART-CC, KP, and VA
2/3 COMPAAAS 三方:ART-CC、KP 和 VA
- 批准号:
10242196 - 财政年份:2017
- 资助金额:
$ 60.76万 - 项目类别:
Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients
以初级保健为基础的干预措施,以减少艾滋病毒患者的饮酒
- 批准号:
8718954 - 财政年份:2012
- 资助金额:
$ 60.76万 - 项目类别:
Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients
以初级保健为基础的干预措施,以减少艾滋病毒患者的饮酒
- 批准号:
8449412 - 财政年份:2012
- 资助金额:
$ 60.76万 - 项目类别:
Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients
以初级保健为基础的干预措施,以减少艾滋病毒患者的饮酒
- 批准号:
8906707 - 财政年份:2012
- 资助金额:
$ 60.76万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 60.76万 - 项目类别:
Research Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 60.76万 - 项目类别:
Standard Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 60.76万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 60.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 60.76万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 60.76万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 60.76万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 60.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 60.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 60.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)